Y-Intercept (HK)’s Alaunos Therapeutics TCRT Stock Holding History

Y-Intercept (HK)’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-281	Closed	-$27.4K	–	1528
2022 Q4	$27.4K	Buy	+281	New	+$40.7K	﹤0.01%	934
2022 Q3	–	Sell	-167	Closed	-$31K	–	1264
2022 Q2	$31K	Buy	+167	New	+$16K	﹤0.01%	775
2021 Q2	–	Sell	-84	Closed	-$42K	–	890
2021 Q1	$42K	Buy	+84	New	+$52.3K	0.01%	595

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Y-Intercept (HK)'s TCRT Position: Q1 2023 in Review

Y-Intercept (HK) sold out of Alaunos Therapeutics (TCRT) in Q1 2023, closing a stake of 281 shares — an estimated $27.4K sold.

Y-Intercept (HK) first reported a position in TCRT in Q1 2021 and held it in 3 quarters. The position peaked at $42K in Q1 2021. 108 funds tracked by Wall St. Rank hold TCRT as of Q1 2023.

Y-Intercept (HK) reported no remaining Alaunos Therapeutics position as of Q1 2023 after selling out during the quarter.
Y-Intercept (HK) sold 281 Alaunos Therapeutics shares in Q1 2023, an estimated $27.4K.
Y-Intercept (HK) first reported a position in Alaunos Therapeutics in Q1 2021 and held it in 3 quarters.
Y-Intercept (HK)'s Alaunos Therapeutics position peaked at $42K in Q1 2021.
108 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2023.

Based on Y-Intercept (HK)'s 13F filing for Q1 2023, filed 9 May 2023.